Anpac Bio’s Liquid Biopsy Tests Catch 26+ Early-Stage Cancers in Single Blood Test!

SACRAMENTO, Calif.Feb. 7, 2018 /PRNewswire/ — Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners, are celebrating  “National Cancer Prevention Day” (#NationalCancerPreventionDay – February 7, 2018) by confirming a new, global milestone:

Anpac Bio’s proprietary “Cancer Differentiation Analysis” (CDA) liquid biopsy technology now identifies over 26 different cancers with a single, standard blood test – usually at its earliest stages!

Comprehensive research validity data from 60,000+ cases, and independently-corroborated by world-renowned hospitals and cancer research leaders, demonstrate Anpac Bio’s CDA diagnostics consistently detects 26+ cancers — with a sensitivity and specificity rate range of 75%-90%. And it does so without any harmful side effects in patients; generating far fewer “false positives”; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

World-renowned, Second Military Medical University and its affiliated Changhai Hospital (CH) in Shanghai, China, have conducted 4,000+ CDA liquid biopsy tests since 2014. Submitting Lung, Esophageal Cancer, and cancer-free control group blood samples, “blinded” to Anpac Bio, CH concluded CDA is a remarkably accurate, non-invasive test, supporting both early diagnosis, and monitoring treatment effectiveness, prognosis, and recurrence.

“Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as potentially a good tool for treatment assessment for Lung Cancer and Esophageal Cancer than traditional tumor markers,” reports Dr. Jun-Jie Wu, Deputy Chief Physician, CH Department of Oncology. “It (CDA) can also play a good role in complementing chest CT (Computerized Axial Tomography) screening for pulmonary nodules. The existing data suggests that CDA technology is a promising technology in the field of diagnosis and treatment assessment of Lung Cancer and cancer of the Esophagus.”

Described as “game changing”, and receiving the, “Breakthrough Innovation Award”, at the World Nobel Prize Laureate Summit; and named, “Most Promising Cancer Screening Company”, at the 2017 Global Precision Medicine IndustryAwards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods.

The Oncology Department of Shanghai Changzheng Hospital (SCH) corroborates these results. Since 2016, SCH has conducted two comprehensive clinical research studies of Anpac Bio’s CDA’s liquid biopsy technology. Submitting over 500 healthy “control” group; “high-risk” group (those genetically or environmentally pre-disposed to developing cancer); and independently-diagnosed and “confirmed cancer” group blood samples; for CDA analysis.

According to study director and SCH Deputy Professor Dr. Yuan Sheng Zang: “Initial results indicated that CDA technology has better sensitivity and specificity for early-stage cancer screening than that of traditional tumor markers. The evaluation on the significance of CDA technology in prognosis is ongoing. The existing research data suggest that CDA technology has a good prospect in the field of cancer diagnosis and prognosis.”

Pioneering liquid biopsy research (launched in 2008), Anpac Bio is already, fully-commercialized and generating revenue from Fortune 500 corporate, insurance, medical, research, and individual (“over the counter”) testing; while most competing “liquid biopsy” research remains in the laboratory and unavailable to the general public (for perhaps years).

Additionally, competing tests generally measure only single/few sample indicators (such as gene mutations that may indicate a patient’s increased risk or probability of potentially developing cancer at some point). Anpac Bio’s CDA is a “functional biology” test – providing medical professionals important information regarding actual disease signals present in the patient’s body at the moment of blood draw.

CDA’s independently-confirmed, very early stage cancer and pre-cancerous disease detection’s efficiency and accuracy is due to the technology’s multi-level and multi-parameter, patented design. With over 200 CDA-related patent applications worldwide (65+ currently issued), CDA’s integrated system measures numerous protein, molecular, cellular, and other factors, to identify disease signals. By enhancing signal detection and processing, while reducing “noise”, the collected data is subsequently analyzed using Anpac Bio’s proprietary algorithms.

The resulting data is then assigned an overall value, called “CDA Value”, indicating cancer incidence risk level (the higher the CDA Value, the higher cancer risk). CDA’s accuracy and advantages have been verified in previous studies, and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO), the Breast Cancer Symposium, and the World Nobel Prize Laureate Summit.

“Every day, our company hears of other, potential ‘liquid biopsy’ tests that report ‘someday’ may be used to catch cancer,” states Dr. Chris Yu, Anpac Bio Chief Executive Officer. “Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia’s most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. We’re very proud that our CDA devices have advanced well-beyond the laboratory and are processing real tests for real people – saving lives every day. On this ‘National Cancer Prevention Month‘, Anpac Bio and our medical partners want the world to know: ‘Someday’ is now!”

 

Anpac Bio Surpasses 100 Case Milestone Detecting Disease in Patients Deemed ‘Cancer Free’ by Traditional Screening

SACRAMENTO, Calif.Dec. 27, 2017 — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week surpassing a new, international record. Anpac Bio’s breakthrough, proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy technology identified the earliest cancer and pre-cancerous disease signals in over 100 individuals previously deemed “cancer free” by other traditional, standard-of-care screening tests.

Since it’s inception, Anpac Bio has conducted general population screening to identify individuals with potential cancer risk. Among them, 100 people labeled “cancer free” by traditional, “standard-of-care” screening tests (such as imaging or annual medical check-up), were flagged by CDA at high-risk of cancer or pre-cancerous conditions. Due to the CDA results, more comprehensive medical testing was conducted; and the patients were subsequently diagnosed with early-stage disease. The CDA test caught disease signals missed by traditional screening tests.

“Our company is commemorating this holiday season by celebrating the most important gift we are able to give: the gift of life,” states Dr. Yu. “Our employees are so proud that our technology helps medical professionals identify and ‘screen out’ early stage or pre-cancerous diseases often missed by other tests. By catching these signals early, patients have the most potential medical options to successfully beat the disease; and go on to live healthy, happy lives!”

Described as “game changing”, and receiving the, “Breakthrough Innovation Award”, at the World Nobel Prize Laureate Summit; and named, “Most Promising Cancer Screening Company”, at the Global Precision Medicine Industry AwardsAnpac Bio’s CDA technology effectively reinvents early cancer screening and detection.

By analyzing simple, standard, blood tests using Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, CDA identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing.

Comprehensive research validity data from 60,000+ cases demonstrate CDA consistently detects 26+ cancers — with 75%-90% sensitivity and specificity rates — usually at its earliest stages.

Pioneering “liquid biopsy” research since 2008, Anpac Bio has filed 200 CDA patent applications worldwide – 65+ issued currently; and employs over 100 globally.

“Hearing from people that beat disease because CDA caught it early is a gift we never get tired of giving!”

Anpac Bio Wins Global Precision Medicine Industry Award: 2017 ‘Most Promising Cancer Screening Company’

SACRAMENTO, Calif.July 17, 2017 —The Global Precision Medicine Industry Awards leadership named international life sciences corporation Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio”), the 2017, “Most Promising Cancer Screening Company” award winner; in recognition of Anpac Bio’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy cancer screening and diagnostic support services.

Anpac Bio CEO Dr. Chris Yu proudly accepted the 2017 Global Precision Medicine Industry Award for “Most Promising Cancer Screening Company” from Award Judge, Professor Xu Chongren, Executive Vice President, School of Life Sciences at Peking University; at the China & America Precision Medicine Forum in Shanghai, China. The award recognized Anpac Bio’s Cancer Differentiation Analysis liquid biopsy “diagnostics services excellence” in identifying early stage cancer. Photo courtesy of Anpac Bio.

Citing Anpac Bio’s, “excellence in diagnostics services”, the Global Precision Medicine Industry Award was presented to Anpac Bio Chief Executive Officer Dr. Chris Yu at the international China America Precision Medicine Forum in Shanghai, China. The Global Precision Medicine Industry Awards recognize individuals, organizations, hospitals, and solution providers worldwide that demonstrate “an unparalleled ability to succeed and have continually set standards of excellence,” supporting medical professionals that provide patients precision medicine solutions.

“Our Anpac Bio team is very proud to accept this very prestigious, international honor,” states Yu. “We are happy that the Global Precision Medicine Industry recognized CDA as a valuable and effective tool supporting patient diagnosis. Multiple research studies indicate the sooner cancer is detected, the better opportunity there is to create the precise medicine needed to best combat the disease with minimal side effects. We are happy Anpac Bio’s CDA technology identifies cancer at its earliest stages for medical professionals to facilitate effective precision treatments; and ultimately increase patient opportunities for a cure.”

Described as “game changing” in World Nobel Prize Laureate Summit publications, Anpac Bio’s proprietary CDA medical devices and liquid biopsy screening services effectively reinvent early cancer detection. By analyzing simple, standard blood tests, and applying Anpac Bio’s multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably greater sensitivity, specificity and accuracy than most current, conventional screening/diagnostic methods.

Comprehensive research validity data from 40,000 cases (to date) indicate CDA far exceeds existing or competing screening technologies — revealing a sensitivity and specificity rate range of 75%-90% for over 26 different types of cancer – most at the diseases’ earliest stages. And it does so without any harmful side effects in patients; generating far fewer “false positives”; at a cost, substantially lower than traditional testing (such as imaging); and generating results within minutes of sample submission.

Attracting corporations and researchers worldwide, the China & America Precision Medicine Forum‘s mission is to, “Deepen Bilateral Cooperation; Enabling Successful Implementation of Precision Medicine 2.0.”  For further information regarding the annual event: www.pmf-annual.com.

Anpac Bio Surpasses 40,000 Case Study Milestone ‘Liquid Biopsy Pioneer’ Serving Individual, Medical, Insurance & Corporate Customers.

SACRAMENTO, Calif., March 28, 2017 /PRNewswire/ — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 40,000 cases worldwide of the company’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests.

Described as “game changing”, in World Nobel Prize Laureate Summit publications, Anpac Bio’s CDA medical devices and technology effectively reinvents early cancer screening and detection. By analyzing simple, in vitro, liquid or “Blood Biopsies”, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing.

Comprehensive research validity data from the 40,000 cases processed to date indicate Anpac Bio’s CDA diagnostics far exceed existing or competing technologies – revealing a sensitivity and specificity rate range of 75%-90% for over 16 different types of cancer – most at the disease’s earliest stages.

“Since our company launched in 2008, we have really pioneered the ‘liquid biopsy’ space,” states Dr. Yu. “Because our CDA devices have already been approved by international regulatory bodies, and our research has been published and presented before respected scientific organizations, like the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in really great demand right now. We’ve processed over 40,000 CDA tests for individuals; and organizations such as health systems, insurance companies, corporations, and educational institutions. We’re very proud our CDA devices have advanced beyond the laboratory, and are processing real tests for real people. And we have dozens of testimonials from people saying our CDA tests detected their early-stage cancer and saved their lives. At this rate, we project to double our CDA cases worldwide and save many more lives, by 2018!”

Anpac Bio maintains research and development, and manufacturing operations, in six sites worldwide, employing over 100 people. Filing over 150 CDA technology-related patent applications internationally to date, the company presented its latest research results, “Investigations of a novel diagnostic technology for colorectal cancer”, at the ASCO 2017 Gastrointestinal Cancers Symposium.

Anpac Bio proud to sponsor the inaugural ‘Anpac Bio World Youth Innovation Forum’, at 2016 World Nobel Prize Laureate Summit, featuring the theme”Serendipity in Science”

Seven Nobel Prize Laureates and over 20 internationally acclaimed researchers and scientists, are presenting at the third annual, World Nobel Prize Laureate Summit in Chengdu, China, September 2-3, 2016. The 2016 WNPLS’ will feature three programs of scientific exploration: 1) Anpac Bio World Youth Innovation Forum; 2) International Symposium for Precision Medicine; and 3) the Bio-Pharmaceutical Industry Forum.

 International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. ...

Corporate sponsor Anpac Bio-Medical Science Company will host WNPLS’ Program I: “Anpac Bio World Youth Innovation Forum” (ABWYIF). Featuring the theme, “Serendipity in Science”, the ABWYIF will differ from many scientific meetings by focusing on the importance of “chance” in the process of scientific research. Presenting Nobel Laureates will share with thousands of young scientists their own, personal experiences of scientific inquiry, challenges, failures, and disruptions, before eventually achieving their Nobel Prize Award-winning breakthroughs.

The ABWYIF participating Nobel Prize Laureates will present at:

  • Richard J. Roberts, WNPLS Co-Chair & 1993 Nobel Laureate, Physiology or Medicine:
    • 9/2/2016: 13:30 pm
    • 9/3/2016: 09:50 am
  • Daniel Kahneman, 2002 Nobel Laureate, Economic Sciences & 2016 WNPLS Speaker
    • 9/2/2016: 13:40 pm
  • Sheldon L. Glashow, 1979 Nobel Laureate, Physics & 2016 WNPLS Speaker
    • 9/2/2016: 13:45 pm
  • Martin L. Chalfie, 2008 Nobel Laureate, Chemistry & 2016 WNPLS Speaker
    • 9/2/2016: 14:30 pm
  • Craig C. Mello, 2006 Nobel Laureate, Physiology or Medicine & 2016 WNPLS Speaker
    • 9/2/2016: 15:15 pm
  • Harald zur Hausen, 2008 Nobel Laureate, Physiology or Medicine & 2016 WNPLS Speaker
    • 9/2/2016: 16:00 pm
  • Aaron Ciechanover, 2004 Nobel Laureate, Chemistry & 2016 WNPLS Speaker
    • 9/3/2016: 09:05 am

Six Nobel Prize Laureate's and over 20 internationally acclaimed researchers and scientists, will present at the third annual, "World Nobel Prize Laureate Summit" (WNPLS) in Chengdu, China, September 1-3, 2016. The 2016 WNPLS' will feature three programs of scientific exploration: 1) "Anpac Bio World Youth Innovation Forum"; 2) "International Symposium for Precision Medicine"; and 3) the "Bio-Pharmaceutical Industry Forum".

Anpac Bio will post highlights of the #WNPLS2016 and #ABWYIF on AnpacBio.com and the Anpac Bio LinkedIn pages throughout the event.

“Anpac Bio-Medical Science Company is very proud to sponsor the inaugural ‘Anpac Bio World Youth Innovation Forum’, at this year’s ‘World Nobel Prize Laureate Summit’,” states Chris Yu, Anpac Bio CEO and ABWYIF Moderator. “Our company’s mission is to foster novel and innovative technology to detect and treat disease. Many of our breakthroughs were the result of both persistence and ‘Serendipity in Science.’ We hope that the Laureates’ presentations will demonstrate through hard work, overcoming and investigating obstacles, and ‘following the science’, promising young scientists will be inspired to realize their own Nobel dreams!”

Led by Zhan Qimin, Director of China’s State Key Laboratory of Molecular Oncology, WNPLS’ Program II, the “International Symposium for Precision Medicine”, will highlight research advancements and breakthroughs in Precision Medicine – particularly impacting cancer research. Among the subjects presented in WNPLS Program II: Cellular and Molecular Biology, Chemistry in Cancer, Tumor Genesis, Clinical Research Trials, Epidemiology, Endocrinology, Targeted Molecular Therapy, and Immunology, among others.

WNPLS’ Program III is the “Bio-Pharmaceutical Industry Forum” – encouraging WNPLS participants to build new connections with Bio-Pharmaceutical contemporaries, while connecting in lively and thought-provoking discussions, and learning directly from world-renowned leaders engaging Bio-Pharmaceutical advancements in the ongoing battle against cancer.

The meeting of international researchers and scientists at the WNPLS is due to the cooperation of a multi-national coalition, including: International Society of Scientific Communications for Nobel Prize Laureates (ISSCNL); China Association of Chinese Medicine; Chinese Medical Doctor Association; China International Conference Center for Science and Technology; Technology World Nobel Medical Media Company; sponsors; Chengdu Provincial Government; the Chengdu Hi-Tech Industrial Development Zone; and others.

“The vision of the World Nobel Prize Laureate Summit is to bring the world’s most eminent scientists together in China, to organize and improve collaborative efforts with their counterparts, and to invigorate a new generation of young students and scientists,” states Roberts. “I hope that the participants attending this meeting will find the talks inspirational and thought-provoking; and will be stimulated to make groundbreaking discoveries that will revolutionize the biosciences and benefit mankind.”

Related Links

Anpac Bio CEO Keynote Speaker at UC Biomedical & Engineering Entrepreneurship Academy

SACRAMENTO, Calif., July 8, 2016  — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, will deliver the Keynote Address to award-winning life and technical science students, faculty, administration, corporate partners, officials, and general public, to launch the University of California Biomedical & Engineering Entrepreneurship Academy (BMEA), Monday, July 11, 2016 at 6 pm.

Hosted by/at the University of California, Davis Institute for Innovation and Entrepreneurship (Institute) and co-sponsored by UCD’s Biomedical Engineering DepartmentSchool of MedicineSchool of Veterinary Medicine, Graduate School of Management and Office of Research, the BMEA is considered one of UC’s premiere programs for commercializing science and engineering innovations. BMEA attendees, recognized by their UC campus leadership statewide as aspiring and early-stage scientific innovators, are graduates/undergraduates, postdoctoral research fellows, and life sciences/biomedical engineering faculty, that receive deep immersion in business development and other skills necessary to move their research out of the lab and successfully into the marketplace.

Dr. Yu, an accomplished serial entrepreneur, innovative physicist, and pioneering inventor, will present, “Game Changing Innovation: An Unconventional Path to Success,” sharing with attendees how his own road to success was not always smooth. Several times, Dr. Yu had to challenge the conventional thought and leadership of the day, to achieve breakthrough science and technology advancement. His speech will also provide practical tips, tools, and advice for achieving career success through true innovation and disruption; offer suggestions on recruiting appropriate mentors to assist and champion efforts/ideas; and encourage attendees to challenge conventional thought/leadership if necessary, to achieve long-lasting and profound breakthroughs benefiting mankind.

The BMEEA launch event featuring Dr. Yu’s Keynote Address, is open and free to the public: https://www.eventbrite.com/e/entrepreneurship-academy-keynote-mixer-featuring-dr-chris-yu-anpac-bio-medical-tickets-25842764404.

Anpac Bio also underwrote five, “Anpac Bio-Medical Innovation & Entrepreneur Fellowships” to UC students statewide that demonstrate particular promise to participate in September’s University of California Entrepreneurship Academy (UCEA).

“We are very excited and proud to enter into this new partnership with Anpac Bio-Medical Science Company and host Dr. Yu as the Academy’s Keynote speaker,” states Cleveland Justis, Institute Executive Director. “The Anpac-sponsored fellowships will allow us the funding and flexibility to recruit and award life science’s brightest minds, most talented academics, and worthy participants displaying promise as entrepreneurs or ‘corporate intrepreneurs’, to attend our academies. Anpac’s sponsorship of the Biomedical and Engineering Entrepreneurship Academy will underwrite a terrific event and attract top-notch keynote speakers like Dr. Yu, to inspire our academy students.”

Related Links

 

Anpac Bio-Medical Science Pledges $50,000 to UC Davis ChildFamily Institute for innovation and Entrepreneurship

Anpac Fellowships Underwrite University of California Students to Attend Scientific Innovation Academies

SACRAMENTO, Calif., Jan. 7, 2016 — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, has pledged $50,000 to the University of California, Davis Child Family Institute for Innovation and Entrepreneurship (UCDCFIIE) to underwrite student fellowships and support UC Davis’ annual Biomedical and Engineering Entrepreneurship Academy.

Anpac’s $10,000 per year/five-year commitment will underwrite two UCDCFIIE programs annually: fellowships at the UC Entrepreneurship Academy and sponsorship of UC Davis’ annual Biomedical and Engineering Entrepreneurship Academy launch event.

The annual “Anpac Bio-Medical Innovation & Entrepreneur Fellowships” will underwrite five UC students from throughout California to participate in UCDCFIIE’s successful UC Entrepreneurship Academy (UCEA). Considered one of UC’s premier programs for commercializing science and engineering innovations, the UCEA is a springboard for moving research out of the lab and into the world, providing deep immersion in business planning for aspiring and early-stage scientific innovators.

In addition to the fellowships, Anpac will underwrite UC Davis’ Biomedical and Engineering Entrepreneurship Academy (UCDBMEA) opening event.

The UCDBMEA is co-sponsored by the UC Davis Biomedical Engineering Department, School of Medicine, School of Veterinary Medicine, Office of Research and the Child Family Institute for Innovation and Entrepreneurship. The academy’s opening event attracts faculty, lab clinicians and postdoctoral students, as well as UC and other academic leaders, corporate and external partners, and elected officials, among others. Anpac Bio-Medical will underwrite and host this event and partner with UC Davis to recruit world-renowned scientists as keynote speakers.

“We are very excited and proud to enter into this new partnership with Anpac Bio-Medical Science Company,” states Cleveland Justis, UCDCFIIE executive director. “The Anpac-sponsored fellowships will allow us the funding and flexibility to recruit and award life science’s brightest minds, most talented academics, and worthy participants displaying promise as entrepreneurs or ‘corporate intrepreneurs,’ to attend our academies. Anpac’s sponsorship of the Biomedical and Engineering Entrepreneurship Academy will underwrite a terrific launch event and attract world-renowned keynote speakers to inspire our academy students. We are honored that Anpac values our institute’s mission and goals. And we look forward to a long and positive relationship with Anpac as we continue to grow our programs and encourage the next generation of scientific innovation.”

Related Links

Anpac Bio-Medical Presenting ‘Breakthrough’ Cancer Screening Tech/Research At Breast Cancer Symposium

SACRAMENTO, Calif., Sept. 16, 2015 — Anpac Bio-Medical Science Company Chief Executive Officer Dr. Chris Yu and Anpac scientists will be presenting “breakthrough,” Breast Cancer screening and early detection research results at the upcoming “Breast Cancer Symposium” in San Francisco, California, September 25-27, 2015.

Reporting outcomes generated through Anpac’s novel, non-invasive, “Cancer Differentiation Analysis” (CDA) technology, Anpac’s team will share with Symposium attendees Anpac’s consistent Breast Cancer detection sensitivity and specificity rates of over 80% to date (versus standard/traditional early detection tests, generating an approximately 30% sensitivity/specificity rate).

Published earlier this year as “game changing”, by the Nobel Prize Laureate Summit on Biomedical Science (NPLS), research indicates Anpac’s CDA medical devices effectively reinvent early Breast Cancer screening and detection. By analyzing simple, in vitro, whole, “Blood Biopsies”, and applying Anpac’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac’s CDA technology identifies Breast Cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional Breast Cancer early screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing (such as imaging).

Of most importance to Symposium participants, Anpac’s CDA technology can reveal threatening Breast Cancer cells, before they form into tumors – key to patient survival rates. According to Cancer Research U.K., more than 90% of women diagnosed with breast cancer at the earliest stage survive their disease for at least five years; compared to around 15% for women diagnosed with the most advanced stage of disease (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival#heading-Three).

The scientific Abstract outlining Anpac’s CDA Breast Cancer research samples/method, results, etc., will post September 25.

“We are excited to share our CDA findings at the Breast Cancer Symposium,” states Dr. Yu. “Our study results are very encouraging. And we hope by sharing them that we can form alliances with other Breast Cancer advocacy organizations, to expedite and launch CDA Breast Cancer clinical trials early next year. Working quickly and in partnership, we can save millions of lives through Anpac CDA screening.”

The Breast Cancer Symposium, co-sponsored by the American Societies of Breast Cancer Surgeons, Clinical Oncology, Radiation Oncology, and Surgical Oncology, is an educational, collaborative forum highlighting clinically relevant, translational science, affecting current breast cancer management.

Related Links

©2019 Anpac Bio-Medical Science Co., Ltd.
;